Artesunate
- Generic Name
- Artesunate
- Brand Names
- Artesunate Amivas
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O8
- CAS Number
- 88495-63-0
- Unique Ingredient Identifier
- 60W3249T9M
- Background
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin.
Artesunate was granted FDA approval on 26 May 2020.
- Indication
Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.
- Associated Conditions
- Acute Uncomplicated Plasmodium Falciparum Malaria, Malaria, Cerebral, Severe Malaria
- Associated Therapies
- -
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT06294912
- Locations
- 🇦🇺
USC Clinical Trials Brisbane (South Bank) ( Site 0001), South Brisbane, South Australia, Australia
Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 90
- Registration Number
- NCT05750459
- Locations
- 🇺🇬
Makerere University - Infectious Diseases Institute, Kampala, Uganda
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Frantz Viral Therapeutics, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05555862
- Locations
- 🇺🇸
Laser Surgery Care, New York, New York, United States
🇺🇸Anal Neoplasia and Cancer Research and Education Center, San Francisco, California, United States
🇺🇸Anal Dysplasia Clinic MidWest, Chicago, Illinois, United States
Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2023-05-23
- Target Recruit Count
- 40
- Registration Number
- NCT04713631
- Locations
- 🇮🇳
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 200
- Registration Number
- NCT04706130
- Locations
- 🇰🇭
Institut Pasteur du Cambodge, Phnom Penh, Cambodia
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Susanne Arnold
- Target Recruit Count
- 13
- Registration Number
- NCT04374019
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
- Conditions
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 2900
- Registration Number
- NCT04330690
- Locations
- 🇨🇦
Health Sciences Centre, Winnipeg, Manitoba, Canada
🇨🇦Trillium Health Partners -Mississauga Site, Mississauga, Ontario, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Alberta, Canada
Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 90
- Registration Number
- NCT03214731
- Locations
- 🇨🇳
The 1st Affiliated Hospital, Sun Yet-sen University, Guangzhou, Guangdong, China
Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- The 108 Military Central Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03093129
- Locations
- 🇻🇳
108 Military Central Hospital, Hanoi, Vietnam
Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2019-12-02
- Target Recruit Count
- 62
- Registration Number
- NCT02996695
- Locations
- 🇲🇱
University of Bamako - Epidemiology of Parasitic Diseases - Malaria Research and Training Center, Sikasso, Mali
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.